Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Stocks in Europe ended Monday's session slightly higher, as investors reacted to more disappointing economic news out of the ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Shares of Novo Nordisk (CSE: NOVOb) continued their upward momentum on Tuesday, rising over 5%, following gains on Monday.

FRANKFURT: Europe’s STOXX 600 closed slightly higher at the start of a holiday-shortened week, as a spike in Novo Nordisk ...

Health insurers such as UnitedHealth Group and Cigna also recovered some of their recent losses following public controversy about industry practices in the wake of the assassination of UnitedHealth ...

EUROPE’S Stoxx 600 closed slightly higher at the start of a holiday-shortened week, as a spike in Novo Nordisk shares boosted ...

The FDA initially rejected the marketing application for Alhemo in 2022, asking for additional data on dosing and monitoring.